The COVID-19 pandemic has ushered a new era in vaccine development. Traditional vaccines based on peptide, protein, and viral vectors have given way to new technologies utilizing DNA and mRNA as antigens to build a protective immune response. Biotech companies such as Moderna and BioNTech have pioneered the use of mRNA as vaccine against COVID-19 demonstrating not only proof-of-concept but also effective viral prevention in large-scale Phase 3 clinical trials. Derived from an alphavirus genome, self-amplifying mRNA (SAM) encodes the alphaviral replicase and a gene of interest (GOI) which enables replication of RNA upon delivery into the cytoplasm. This unique feature of self-amplification distinguishes from the mRNA counterparts. Abnova has developed a COVID-19 SAM RBD (receptor-binding domain) formulated in lipid nanoparticle (LNP) which generates higher antibody titer response than mRNA, setting the precedence for the next-generation vaccines.

SAM Construct


SAM Preparation


SAM Immunization


SAM Data

* Abnova COVID-19 SAM Universal Vaccine Under Patent Filing 2021

For any inquiry, please contact : OEM@abnova.com

For any inquiry, please contact
We have placed cookies on your device to make our website better. If you continue using our website, we assume you agree to it. You can learn more details here .